PMID- 32322437
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2162-3619 (Print)
IS  - 2162-3619 (Electronic)
IS  - 2162-3619 (Linking)
VI  - 9
DP  - 2020
TI  - Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic 
      anemia: a systematic review and meta-analysis.
PG  - 6
LID - 10.1186/s40164-020-00163-5 [doi]
LID - 6
AB  - BACKGROUND: The efficacy and safety of rituximab (RTX) on hemolytic anemia (HA) 
      is unknown. Therefore we retrospectively analyze the efficacy and safety of RTX 
      in autoimmune hemolytic anemia (AIHA) and microangiopathic hemolytic anemia 
      (MAHA) from the previous literature. METHODS: Data in clinical trials and 
      observational studies were collected from PubMed, Cochrane, Embase, and Google 
      Scholar until Oct 15, 2018. The efficacy and safety of RTX in patients with AIHA 
      or MAHA were assessed and overall response rates (ORRs), complete response rates 
      (CRRs), adverse events (AEs) and relapse rates (RRs) were extracted if available. 
      A meta-analysis was performed with a random-effects model, estimating mean 
      proportions in all studies, and relative rates in comparative studies. RESULTS: 
      After quality assessment, a total of 37 investigations encompassing 1057 patients 
      eligible for meta-analysis were included. Pooled mean proportion of ORR was 0.84 
      (95% confidence interval [CI] 0.80-0.88), and that of CRR was 0.61 (95% CI 
      0.49-0.73). Mean AE rate was 0.14 (95% CI 0.10-0.17), and mean RR was 0.21 (95% 
      CI 0.15-0.26). Relative ORR was 1.18 (95% CI 1.02-1.36), and relative CRR was 
      1.17 (95% CI 0.98-1.39) fold more than the respective non-RTX counter parts. 
      Relative AE rate was 0.77 (95% CI 0.36-1.63), and relative RR was 0.93 (95% CI 
      0.56-1.55) fold less than the respective non-RTX counter parts. CONCLUSION: RTX 
      is more effective than the treatments without RTX for AIHA and MAHA and is 
      well-tolerated.
CI  - (c) The Author(s) 2020.
FAU - Chao, Shih-Hsuan
AU  - Chao SH
AD  - 1Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan. GRID: 
      grid.260770.4. ISNI: 0000 0001 0425 5914
FAU - Chang, Yuh-Lih
AU  - Chang YL
AD  - 2Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan. GRID: 
      grid.278247.c. ISNI: 0000 0004 0604 5314
FAU - Yen, Jiin-Cherng
AU  - Yen JC
AD  - 1Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan. GRID: 
      grid.260770.4. ISNI: 0000 0001 0425 5914
FAU - Liao, Hsien-Tzung
AU  - Liao HT
AD  - 3Division of Allergy Immunology & Rheumatology, Taipei Veterans General Hospital, 
      201 Shih-Pai Rd Sec 2, Taipei, 112 Taiwan. GRID: grid.278247.c. ISNI: 0000 0004 
      0604 5314
FAU - Wu, Tsai-Hung
AU  - Wu TH
AD  - 4Division of Nephrology, Taipei Veterans General Hospital, Taipei, Taiwan. GRID: 
      grid.278247.c. ISNI: 0000 0004 0604 5314
FAU - Yu, Chia-Li
AU  - Yu CL
AD  - 5Division of Rheumatology Immunology & Allergy, Department of Internal Medicine, 
      National Taiwan University Hospital, Taipei, Taiwan. GRID: grid.412094.a. ISNI: 
      0000 0004 0572 7815
FAU - Tsai, Chang-Youh
AU  - Tsai CY
AUID- ORCID: 0000-0002-4154-4018
AD  - 3Division of Allergy Immunology & Rheumatology, Taipei Veterans General Hospital, 
      201 Shih-Pai Rd Sec 2, Taipei, 112 Taiwan. GRID: grid.278247.c. ISNI: 0000 0004 
      0604 5314
FAU - Chou, Yueh-Ching
AU  - Chou YC
AD  - 2Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan. GRID: 
      grid.278247.c. ISNI: 0000 0004 0604 5314
LA  - eng
PT  - Journal Article
DEP - 20200415
PL  - England
TA  - Exp Hematol Oncol
JT  - Experimental hematology & oncology
JID - 101590676
PMC - PMC7161265
COIS- Competing interestsWe declared that we have no competing interests.
EDAT- 2020/04/24 06:00
MHDA- 2020/04/24 06:01
PMCR- 2020/04/15
CRDT- 2020/04/24 06:00
PHST- 2020/02/09 00:00 [received]
PHST- 2020/03/28 00:00 [accepted]
PHST- 2020/04/24 06:00 [entrez]
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2020/04/24 06:01 [medline]
PHST- 2020/04/15 00:00 [pmc-release]
AID - 163 [pii]
AID - 10.1186/s40164-020-00163-5 [doi]
PST - epublish
SO  - Exp Hematol Oncol. 2020 Apr 15;9:6. doi: 10.1186/s40164-020-00163-5. eCollection 
      2020.